.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Merck
Covington
Cipla
Citi
Moodys
Daiichi Sankyo
Novartis
AstraZeneca
Chubb

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,453,446

« Back to Dashboard

Which drugs does patent 5,453,446 protect, and when does it expire?


Patent 5,453,446 protects AZILECT and is included in one NDA. There has been one Paragraph IV challenge on Azilect.

This patent has seventy-four patent family members in thirty-two countries.

Summary for Patent: 5,453,446

Title: Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Abstract:R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
Inventor(s): Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:08/255,046
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-001May 16, 2006ABRXYesNo► Subscribe► Subscribe TREATMENT OF PARKINSON'S DISEASE
Teva
AZILECT
rasagiline mesylate
TABLET;ORAL021641-002May 16, 2006ABRXYesYes► Subscribe► Subscribe TREATMENT OF PARKINSON'S DISEASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,453,446

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel92952Jan 03, 1990

Non-Orange Book Patents for Patent: 5,453,446

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,956,060 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
6,630,514 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,387,612 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease► Subscribe
5,532,415 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof► Subscribe
5,576,353 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds► Subscribe
5,744,500 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,668,181 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression► Subscribe
5,786,390 Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan► Subscribe
6,316,504 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof► Subscribe
5,891,923 R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,453,446

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0812190► Subscribe91191Luxembourg► Subscribe
European Patent Office0812190► SubscribeCA 2005 00039Denmark► Subscribe
European Patent Office0812190► Subscribe300205Netherlands► Subscribe
European Patent Office0812190► SubscribeSPC024/2005Ireland► Subscribe
European Patent Office0812190► Subscribe05C0033France► Subscribe
European Patent Office0812190► SubscribeSPC/GB05/042United Kingdom► Subscribe
European Patent Office0812190► SubscribeC00812190/01Switzerland► Subscribe
European Patent Office0812190► SubscribeC300205Netherlands► Subscribe
European Patent Office0812190► Subscribe31/2005Austria► Subscribe
European Patent Office0828485► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Army
UBS
Cantor Fitzgerald
Queensland Health
Cerilliant
Express Scripts
Johnson and Johnson
Deloitte
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot